Relmada Therapeutics (RLMD) Retained Earnings (2012 - 2026)

Relmada Therapeutics (RLMD) has reported Retained Earnings for 15 consecutive years, with $935.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings rose 37.47% year-over-year to $935.9 million; the TTM figure through Mar 2026 stood at $935.9 million (up 37.47% YoY), while the FY2025 annual figure was $784.7 million, up 222.44% from the prior year.
• Retained Earnings advanced to $935.9 million in Q1 2026 per RLMD's latest filing, from $784.7 million in the prior quarter.
• Across five years, Retained Earnings topped out at $935.9 million in Q1 2026 and bottomed at -$640.9 million in Q4 2024.
• Historically, Retained Earnings has averaged $195.9 million across 5 years, with a median of $602.5 million in 2022.
• Annual changes were most pronounced in 2022 — Retained Earnings tumbled 217.82% — and 2023, when it surged 262.45%.
• Relmada Therapeutics' Retained Earnings stood at $602.5 million in 2022, then tumbled by 193.09% to -$560.9 million in 2023, then dropped by 14.26% to -$640.9 million in 2024, then surged by 222.44% to $784.7 million in 2025, then rose by 19.27% to $935.9 million in 2026.
• Business Quant data shows RLMD's Retained Earnings at $935.9 million in Q1 2026, $784.7 million in Q4 2025, and $687.8 million in Q3 2025.